aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with a mission to address the global health crisis of snakebite envenomation, Ophirex is pioneering the development of the world's first field antidotes for snakebite treatment. The company focuses on creating accessible, effective solutions that can be administered in remote and resource-limited settings, aiming to significantly reduce the mortality and morbidity associated with snakebites. Their flagship product, Varespladib, is designed to be a portable, easy-to-use antidote that can be deployed quickly in emergency situations.
Ophirex has garnered support from notable investors and collaborators in the medical and scientific communities. Their innovative approach has led to significant achievements, including advancements in clinical trials and regulatory milestones. The impact of their work extends globally, offering hope to millions of snakebite victims who previously had limited treatment options. By focusing on scalable and practical solutions, Ophirex is set to revolutionize the field of snakebite treatment and improve public health outcomes worldwide.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Snakebite Treatment
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Government
Geographic Exposure
Global
When was Ophirex founded?
Ophirex was founded in 2015.
Where is Ophirex’s headquarters located?
Ophirex’s headquarters is located in Corte Madera, CA, US.
When was Ophirex’s last funding round?
Ophirex’s most recent funding round was for $37M (USD) in January 2023.
How many employees does Ophirex have?
Ophirex has 23 employees as of Feb 5, 2024.
How much has Ophirex raised to-date?
As of July 05, 2023, Ophirex has raised a total of $53.5M (USD) since Jan 5, 2023.
Add Comparison
Total Raised to Date
$53.5M
USD
Last Update Jan 5, 2023
Last Deal Details
$37M
USD
Jan 5, 2023
Series B
Total Employees Over Time
23
As of Feb 2024
Ophirex Address
Corte Madera,
California
94925
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts